Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Graphene nanoplatelets based products maker Directa Plus upgraded its outlook on revenue and said it had made a strong start to the year.
Audited results for FY2020, expected in mid-May 2021, is now forecast to show revenue of approximately €6.7 million, a further improvement from the previously reported expectation of €6.5 million, the company said.
The Group's current order book stood at approximately €4.3 million, which was expected to be delivered over the rest of FY2021.
Trading in Q1 2021 has been 'strong,' with revenues expected to be around €1.8 million, up 20% from the same period in 2020, it added.
At 8:39am: (LON:DCTA) Directa Plus Plc share price was 0p at 61p